Duality Biologics (Suzhou) Co. Ltd. (DualityBio)

https://www.dualitybiologics.com

DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced four assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing to evolve its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs. *

	Start	2023-04-03 existent
	Industry	antibody-drug conjugate (ADC)
	Industry 2	DB-1311/BNT324 (B7-H3 ADC, Duality Biologics / BioNTech)
	Person	Zhu, John (DualityBio 202304 CEO + Founder formerly 6 Dimensions Capital)

	Region	Shanghai
	Country	China
	Street	#868 YinghuaRoad Unit 1105-1106, Pudong New District
	City	201204 Shanghai
		Address record changed: 2024-08-28

Basic data	Employees	n. a.

		* Document for »About Section«: BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai.

		Record changed: 2025-03-16